Welcome to Cosmo Pharmaceuticals
Cosmo is a speciality pharmaceutical company that aims to become a global leader in the market of optimised therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for Inflammatory Bowel Diseases (IBD), such as Ulcerative Colitis and Crohn’s Disease, as well as for colon infections and selected topically treated Skin Disorders.
Information for remaining BioXell Shareholders - click here for more
Product Pipeline
The company is developing a range of drug projects that are mostly based on its Multi Matrix MMX® technology.
Therapeutic Focus
Inflammatory Bowel Diseases (IBD) are a group of chronic, progressive, recurring and debilitating disorders leading to the damage of the gastro-intestinal tract. The main forms of IBD are Ulcerative Colitis and Crohn’s Disease. Both diseases are clinically similar and may be described as a faulty regulation of the mucosal immune response.
Business Fields
Cosmo is engaged in two distinct fields:
- Development and commercialisation of proprietary drugs, primarily focused on the treatment of Inflammatory Bowel Diseases and colon infections.
- Manufacturing of pharmaceutical products for third parties and the provision of related services.
| Price | 17.00 |
| Date | 30/07/2010 |
| Time | 17:31 CEST |
| Change | 1.00 |
| Market cap | CHF 254.9 mln |
| Data is delayed by approximately 20 minutes | |
Half Year Results 201020-23 September 2010
UBS Global Life Science Conference, New York